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It is well established that several key proteins of the con-
tractile apparatus are phosphoproteins. This includes
myosin binding protein C (MyBP-C), troponin T and tro-
ponin I. It is also generally accepted that phosphorylation
of these proteins alters their functional properties and that
this modulation of function through the action of kinases
and phosphatases plays a role in tuning the contractile
apparatus to physiological demands. The prime example of
this is phosphorylation of troponin I and MyBP-C by PKA
as part of inotropic and lusitropic responses to b-adrenergic
stimulation.
What is considerably less certain is the ‘where’ and
‘when’ of these phosphorylations. The sites of contractile
protein phosphorylation by kinases such as PKA and PKC
have been determined in vitro and the consequences of
changes in phosphorylation at these sites have been
investigated by site directed mutagenesis and transgenic
mouse models. What has not been determined is whether
these predominantly in vitro measurements in puriﬁed
proteins and in rodent models have any relevance to the
human heart in vivo.
Recently several papers have addressed this question
with new techniques and the results have been surprising
and somewhat disconcerting. Phosphorylation in human
and rat troponin I and troponin T has recently been studied
using electrospray ionisation and Fourier transform mass
spectrometry (Zabrouskov et al. 2008; Sancho Solis et al.
2008). The great advantage of this method is that the mass
of the intact protein can be determined with an accuracy
high enough to unambiguously assign the isoform and the
nature and number of post-translational modiﬁcations,
whilst subsequent splitting of the molecular ion can deﬁne
where in the sequence the modiﬁcations are located. When
applied to troponin this method reveals the precise patterns
of troponin I and troponin T phosphorylation isolated from
heart muscle.
According to current literature troponin I is phosphory-
lated in vitro by PKA at Ser22 and 23, by PKC at Ser41,
Ser43 and Thr142 and by PAK1 at Ser149 (Noland et al.
1989; Buscemi et al. 2002; Layland et al. 2005) [for con-
sistency we use the numbering of the native human cardiac
troponin I sequence in which the N-terminal methionine is
removed during post-translational processing (Zabrouskov
et al. 2008)]. Measurements of total phosphorylation indi-
cate that 1.6–2.3 mol of Pi are incorporated per mole of
troponin I but where is the troponin I phosphorylated
(Messer et al. 2009)? One might naturally assume that the
troponin I sites phosphorylated in vitro are those phos-
phorylated in vivo, but under what conditions? Thus far the
new mass spectrometry techniques have been applied to
whole troponin, puriﬁed from healthy unstimulated hearts
by antibody afﬁnity methods, to reveal basal phosphoryla-
tion patterns (Messer et al. 2007; Sancho Solis et al. 2008).
Analysis of human troponin I conﬁrms that Ser22 and 23 are
phosphorylated and constitute approximately half of the
phosphorylation sites whilst a complementary technique of
phosphate afﬁnity SDS–PAGE shows that Ser22 ? Ser23
constitute closer to 2/3 of phosphorylation sites (Messer
et al. 2009). Mass spectrometry further reveals the location
of these and other prominent sites and somewhat surpris-
ingly shows no sign of phosphorylation at Ser41, Ser43,
Thr142 or Ser149. Instead, the remaining 1/2 to 1/3 of
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techniques do not yet distinguish between the two). This
may not be a truly new site: curiously enough, Ser76 was
listed as one of the sites phosphorylated by PKC in the
earliest publications but it has been forgotten over the years
(Noland et al. 1989). This site in human troponinI may have
been a ‘casualty’ of the recent emphasis on rodent models in
which Ser76 is conserved but Thr77 is not. Meanwhile, in
vitro research and increasing use of transgenic mouse
models has concentrated on elucidating the function of the
other sites phosphorylated by PKC (Layland et al. 2005),
which are now found to be largely absent in the heart at least
underbasalconditions.Thesenewstudiesarereminiscentof
studiesofcardiactroponinby
31P-NMRinwhichonlySer22
and Ser23 were found to be phosphorylated, either individ-
ually or together (Beier et al. 1988; Jaquet et al. 1993).
Among the strengths of
31P-NMR is its ability to probe
conformation and environment of phosphate moieties,
however,itsinabilitytodetectlowlevelsofphosphorylation
left open the possibility that key basal phosphorylation sites
were missed in this analysis. The new mass spectrometry
and phosphate afﬁnity SDS-PAGE techniques are much
more sensitive and still do not reveal basal phosphorylation
of widely studied PKC sites in human, rat or mouse heart.
A similar re-emergence of a forgotten site occurs with
troponin T. The earliest reports, based on the now-obsolete
Edman degradation approach to sequencing, identiﬁed Ser1
of cardiac troponin T as a phosphorylation site (and Thr1 in
skeletal muscle; Gusev et al. 1980, 1983). This phosphor-
ylation was apparently constitutive and therefore not
thought to be of importance in beat-to-beat physiological
regulation of the heart. Early
31P-NMR measurements
described two phosphorylation signals for bovine troponin
T, one at Ser1 and another in the C-terminal CNBr frag-
ment (residues 181–285, bovine sequence) (Swiderek et al.
1990). Recent investigations of human heart samples have
conﬁrmed that troponin T phosphorylation is virtually
constant in normal and pathological muscle where troponin
I phosphorylation levels vary enormously (van der Velden
et al. 2003; Messer et al. 2007). A number of other sites in
troponin T, phosphorylated by PKC and CaMKII in vitro
have been identiﬁed and their regulatory signiﬁcance was
studied by site-directed mutagenesis. The phosphorylation
of Thr203 by PKC has been particularly thoroughly
investigated since phosphorylation at this site produced
measurable functional effects (Sumandea et al. 2003).
The mass spectrometry measurements on heart troponin
bring us right back to the initial studies. Troponin T in rat
heart muscle is 100% monophosphorylated, the site of
phosphorylation is almost certainly Ser1 and all possible
sites beyond amino acid 30 have been essentially excluded,
at least under basal conditions (Sancho Solis et al. 2008). In
a previous report, using Pro-Q Diamond phosphoprotein
stain, troponin T phosphorylation in human heart was
calculated to be up to 3 mol Pi per mole. This is probably
in error due to the anomalous behaviour of the phosphate-
chelating Pro-Q Diamond probe when phosphorylation is
on the N-terminal amino acid (Messer et al. 2007, 2009).
On the other hand, there may be signiﬁcant species
differences that need to be evaluated systematically.
The ﬁnal case is MyBP-C. Initially 3 PKA sites were
deﬁned in the cardiac-speciﬁc linker between domains C1
and C2 based on sequence analysis and site-directed
mutagenesis (Gautel et al. 1995). MyBP-C is too big to be
analysed fully intact by current ESI methods but it has been
studied by 2D electrophoresis of heart muscle myoﬁbrils,
followed by mass spectrometry analysis of proteolytic
fragments (Yuan et al. 2006; Duncker et al. 2009). The
presence of 11 spots on 2D electrophoresis, many of which
stain positive for Pro-Q Diamond, established that there are
multiple phosphorylated species and a quantitative mea-
surement indicated 4–5 mol Pi per mol MyBP-C in human
heart (Jacques et al. 2008). In fact, mass spectrometry
identiﬁed ﬁve different sites phosphorylated and only two
of these corresponded to the proposed PKA sites.
This new data should initiate a radical rethink of how
contractile proteins are modulated by phosphorylation in
the heart. The in vitro approach of identifying sites phos-
phorylated in pure contractile proteins and their analysis by
site-directed mutagenesis is useful but should not stand
alone. It is also essential to know the sites phosphorylated
in the intact heart and how they change with physiological
and pathological changes to their environment (Marston
and deTombe 2008). Perhaps the PKC and PAK1 sites
found to be unphosphorylated in the basal ‘healthy’ state
are quite dynamic and this characteristic needs to be
carefully considered in efforts to ‘trap’ phosphorylation on
these sites in vivo. The recent publications show we now
have powerful tools to unambiguously determine the
phosphorylation status of these proteins isolated from
single rodent hearts and from human heart biopsies.
Whilst the PKA sites at serines 22 and 23 of troponin I
and their modulation of Ca
2?-sensitivity and Ca
2?-disso-
ciation kinetics seems to be a sound hypothesis, the role of
PKC, PAK1, AMP kinase and CaMKII phosphorylation in
vivo is now most uncertain. Direct measurements do not
support the hypothesis that increased PKC activity in
failing heart (Bowling et al. 1999) leads to increased
phosphorylation of troponin I or troponin T: in fact total
phosphorylation levels in troponin I and MyBP-C are
reduced in heart failure suggesting that PKC may con-
tribute to down-regulation of the beta-adrenergic system
and may activate phosphatases instead (Neumann et al.
1997; Messer et al. 2007).
It seems we now know less than we thought we did
about the role of post-translational modiﬁcations in
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123modulating cardiac contractile function. This may be partly
due to the oversimpliﬁed view of phosphorylation as a
regulatory signal that switches between low, intermediate
and high levels of occupancy on a few special sites as is
now widely accepted for the Ser22/23 sites in cardiac
troponin I. We should be heartened by the fact that we now
have the tools that will ensure future research can be
directed towards elucidating the physiological functions of
those phosphorylation sites that are dynamically phos-
phorylated by speciﬁc and interesting environmental cir-
cumstances. The new work focuses attention on sites that
show substantial basal phosphorylation, but continued
interest in other phosphorylation sites will depend upon
being able to demonstrate their occupancy in vivo under
physiologically or pathologically relevant conditions.
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